Status update on VB C-02 clinical trial with VB10.16 and immune checkpoint inhibitor atezolizumab - Vaccibody.com
2741
post-template-default,single,single-post,postid-2741,single-format-standard,bridge-core-2.4.3,qode-page-transition-enabled,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-25.7,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

Status update on VB C-02 clinical trial with VB10.16 and immune checkpoint inhibitor atezolizumab

Status update on VB C-02 clinical trial

View press release (PDF)